Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Net Cash Flow (2016 - 2025)

Cytokinetics (CYTK) has disclosed Net Cash Flow for 16 consecutive years, with $97.2 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow changed N/A to $97.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $76.3 million through Dec 2025, changed N/A year-over-year, with the annual reading at $31.1 million for FY2025, 269.32% up from the prior year.
  • Net Cash Flow for Q4 2025 was $97.2 million at Cytokinetics, up from -$20.9 million in the prior quarter.
  • The five-year high for Net Cash Flow was $97.2 million in Q4 2025, with the low at -$143.1 million in Q3 2024.
  • Average Net Cash Flow over 5 years is $2.4 million, with a median of $6.9 million recorded in 2024.
  • The sharpest move saw Net Cash Flow soared 1207.47% in 2023, then crashed 560.92% in 2024.
  • Over 5 years, Net Cash Flow stood at $22.1 million in 2021, then plummeted by 276.69% to -$39.1 million in 2022, then skyrocketed by 134.19% to $13.4 million in 2023, then plummeted by 1171.96% to -$143.1 million in 2024, then soared by 167.89% to $97.2 million in 2025.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at $97.2 million, -$20.9 million, and -$143.1 million for Q4 2025, Q1 2025, and Q3 2024 respectively.